[go: up one dir, main page]

CL2008002161A1 - Compuestos derivados de pirazol de fórmula (i); procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad oclusiva de arterias, angina inestable, paro cardíaco, isquemia, cardiomiopatía, enfermedad de crohn, esclerosis múltiple, dolor neuropático. - Google Patents

Compuestos derivados de pirazol de fórmula (i); procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad oclusiva de arterias, angina inestable, paro cardíaco, isquemia, cardiomiopatía, enfermedad de crohn, esclerosis múltiple, dolor neuropático.

Info

Publication number
CL2008002161A1
CL2008002161A1 CL2008002161A CL2008002161A CL2008002161A1 CL 2008002161 A1 CL2008002161 A1 CL 2008002161A1 CL 2008002161 A CL2008002161 A CL 2008002161A CL 2008002161 A CL2008002161 A CL 2008002161A CL 2008002161 A1 CL2008002161 A1 CL 2008002161A1
Authority
CL
Chile
Prior art keywords
compound
disease
cardiomyopathy
crohn
ischemia
Prior art date
Application number
CL2008002161A
Other languages
English (en)
Inventor
Mattei Patrizio
Binggeli Alfred
Ricklin Fabienne
Aebi Johannes
Green Luke
P Maerki Hans
Hartmann Guido
Roche Oliver
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39816951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002161(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2008002161A1 publication Critical patent/CL2008002161A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos derivados de pirazol; procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad oclusiva de arterias, angina inestable, paro cardiaco, isquemia, cardiomiopatía, enfermedad de Crohn, esclerosis múltiple, dolor neuropático.
CL2008002161A 2007-07-26 2008-07-24 Compuestos derivados de pirazol de fórmula (i); procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad oclusiva de arterias, angina inestable, paro cardíaco, isquemia, cardiomiopatía, enfermedad de crohn, esclerosis múltiple, dolor neuropático. CL2008002161A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113173 2007-07-26

Publications (1)

Publication Number Publication Date
CL2008002161A1 true CL2008002161A1 (es) 2009-05-22

Family

ID=39816951

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002161A CL2008002161A1 (es) 2007-07-26 2008-07-24 Compuestos derivados de pirazol de fórmula (i); procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad oclusiva de arterias, angina inestable, paro cardíaco, isquemia, cardiomiopatía, enfermedad de crohn, esclerosis múltiple, dolor neuropático.

Country Status (15)

Country Link
US (1) US7977358B2 (es)
EP (1) EP2182953A2 (es)
JP (1) JP2010534631A (es)
KR (1) KR20100039416A (es)
CN (1) CN101765430A (es)
AR (1) AR067674A1 (es)
AU (1) AU2008280186A1 (es)
BR (1) BRPI0813836A2 (es)
CA (1) CA2693187A1 (es)
CL (1) CL2008002161A1 (es)
PE (1) PE20090893A1 (es)
RU (1) RU2010106397A (es)
SG (1) SG175583A1 (es)
TW (1) TW200911785A (es)
WO (1) WO2009013211A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4276280B2 (ja) 2005-11-21 2009-06-10 塩野義製薬株式会社 Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物
RU2455285C2 (ru) 2007-05-18 2012-07-10 Сионоги Энд Ко., Лтд. АЗОТСОДЕРЖАЩЕЕ ГЕТЕРОЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ, ОБЛАДАЮЩЕЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ ТИПА 1
AR073578A1 (es) * 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
EA020548B1 (ru) 2008-12-19 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
MX346393B (es) 2009-12-17 2017-03-17 Centrexion Therapeutics Corp Nuevos antagonistas del receptor ccr2 y usos de los mismo.
WO2011151251A1 (en) 2010-06-01 2011-12-08 Boehringer Ingelheim International Gmbh New ccr2 antagonists
JP5999387B2 (ja) * 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｒｔｈ２拮抗薬としてのピラゾール化合物
WO2013042139A1 (en) 2011-09-23 2013-03-28 Advinus Therapeutics Limited Amide compounds, compositions and applications thereof
US9289365B2 (en) * 2011-10-24 2016-03-22 Avon Products, Inc. Compositions and methods for stimulating collagen synthesis in the skin
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
CN106061969B (zh) 2014-01-06 2019-10-29 阿尔戈么迪克斯有限公司 Trpa1调节剂
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
EA038071B1 (ru) 2014-08-21 2021-07-01 Бёрингер Ингельхайм Интернациональ Гмбх СОЕДИНЕНИЕ СПИРО[3H-ИНДОЛ-3,2'-ПИРРОЛИДИН]-2(1H)-ОНА И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ MDM2-p53
EP3227282B1 (en) * 2014-12-02 2019-04-03 F.Hoffmann-La Roche Ag Novel piperidine derivatives
JP2018510155A (ja) 2015-03-19 2018-04-12 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーＥ．Ｉ．Ｄｕ Ｐｏｎｔ Ｄｅ Ｎｅｍｏｕｒｓ Ａｎｄ Ｃｏｍｐａｎｙ 殺菌・殺カビ性ピラゾール
WO2017004537A1 (en) 2015-07-02 2017-01-05 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
UA123905C2 (uk) 2015-10-09 2021-06-23 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіро[3h-індол-3,2'-піролідин]-2(1h)-онові сполуки та похідні як інгібітори мdm2-p53
US20180164221A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US10391987B2 (en) * 2017-05-24 2019-08-27 Trw Automotives U.S. Llc Method for controlling a vehicle
TWI832917B (zh) 2018-11-06 2024-02-21 美商富曼西公司 經取代之甲苯基殺真菌劑
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
UY39189A (es) 2020-05-06 2021-12-31 Fmc Corp Fungicidas de tolilo sustituido y sus mezclas
CN114716389A (zh) * 2021-12-31 2022-07-08 北京岳达生物科技有限公司 一种3,5-二乙基异恶唑-4-羧酸的合成方法
CN117088800B (zh) * 2023-08-18 2024-05-28 龙曦宁（上海）医药科技有限公司 一种5-甲基吡咯烷-3-醇盐酸盐的制备方法
US12441688B1 (en) 2025-01-30 2025-10-14 King Saud University CCR5 inhibitor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6140266A (ja) 1984-08-01 1986-02-26 Morishita Seiyaku Kk ピラゾ−ル誘導体
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5987135A (en) 1997-07-25 1999-11-16 Prc Inc. System and method for controlling and monitoring remote distributed processing system
TWI224597B (en) * 1999-12-03 2004-12-01 Ono Pharmaceutical Co Triazaspiro[5.5]undecane derivatives and a medicine containing the derivatives as an active ingredient
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
DE10149370A1 (de) 2001-10-06 2003-04-10 Merck Patent Gmbh Pyrazolderivate
US7223782B2 (en) 2001-11-01 2007-05-29 Icagen, Inc. Pyrazole-amides and -sulfonamides
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
WO2004047776A1 (fr) 2002-11-20 2004-06-10 L'oreal Utilisation d’un compose pyrazolcarboxamide pour stimuler la pousse des fibres keratiniques et/ou freiner leur chute
EP1599447A1 (en) * 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
DE10315572A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
UA82917C2 (en) * 2003-12-18 2008-05-26 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptor
BRPI0507586A (pt) 2004-02-10 2007-07-03 Hoffmann La Roche moduladores de receptor de quimiocina ccr5
DE102004014296A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8-Triazaspiro[4.5]decan-2-on-Verbindingen
TW200610761A (en) 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
WO2006004027A1 (ja) * 2004-07-01 2006-01-12 Daiichi Pharmaceutical Co., Ltd. ピラゾール誘導体
CN101001852A (zh) * 2004-08-06 2007-07-18 第一制药株式会社 吡唑衍生物
EP1848428A4 (en) 2005-02-18 2012-04-18 Neurogen Corp THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGS
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
CA2623327A1 (en) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
JP5222855B2 (ja) 2006-12-18 2013-06-26 ７ティーエム ファーマ エイ／エス Ｃｂ１受容体のモジュレーター

Also Published As

Publication number Publication date
CA2693187A1 (en) 2009-01-29
US20090029963A1 (en) 2009-01-29
AU2008280186A1 (en) 2009-01-29
BRPI0813836A2 (pt) 2015-01-06
WO2009013211A3 (en) 2009-04-23
TW200911785A (en) 2009-03-16
EP2182953A2 (en) 2010-05-12
RU2010106397A (ru) 2011-09-10
US7977358B2 (en) 2011-07-12
WO2009013211A2 (en) 2009-01-29
SG175583A1 (en) 2011-11-28
AR067674A1 (es) 2009-10-21
JP2010534631A (ja) 2010-11-11
KR20100039416A (ko) 2010-04-15
CN101765430A (zh) 2010-06-30
PE20090893A1 (es) 2009-07-15

Similar Documents

Publication Publication Date Title
CL2008002161A1 (es) Compuestos derivados de pirazol de fórmula (i); procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad oclusiva de arterias, angina inestable, paro cardíaco, isquemia, cardiomiopatía, enfermedad de crohn, esclerosis múltiple, dolor neuropático.
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
ES2531009T3 (es) Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos
CL2007003299A1 (es) Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
CL2008000127A1 (es) Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos
CL2009000915A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd).
CO6390101A2 (es) Compuestos purina
CL2009000914A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CL2008000059A1 (es) Compuestos derivados de espiropiperidina-glicinamida; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hipertension, dismenorrea, fallo cardiaco cronico, ansiedad, t
SV2004001756A (es) Nueva difenilazetidinona con propiedades fisiologicas mejoraradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
ECSP22032016A (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
PE20210928A1 (es) Mezclas pesticidas que comprenden indazoles
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу